Special issue on in vitro MN trial.
In this commentary we are addressing some additional thoughts on the in vitro MN test: its predictivity for in vivo MN assays, its sensitivity, and how the choice of the cell line and the protocol (with or without cytochalasin-B) can influence these aspects. These considerations might help to make the in vitro MN test a reliable, toxicologically relevant and sensitive in vitro genotoxicity test covering both clastogenic and aneugenic events, and predictive for in vivo genotoxicity, in humans as well.
Parry
James M
JM
School of Medicine, University of Wales-Swansea, Swansea, United Kingdom.
Kirsch-Volders
Micheline
M
D024422:Aneugens / Q000633:toxicity*; D002460:Cell Line; D003571:Cytochalasin B / Q000494:pharmacology; D005820:Genetic Testing; D017408:Guidelines as Topic; D006801:Humans; D015162:Micronucleus Tests / Q000379:methods / Q000592:standards*; D012680:Sensitivity and Specificity
D024422:Aneugens; D003571:Cytochalasin B